Study of Blood Test for Detecting Residual Cancer After Surgery and Chemotherapy in Adults with Stage III Colorectal Cancer

What this Trial Is About

Researchers are exploring new ways to improve personalized treatments for stage III colorectal cancer by using circulating tumor DNA ctDNA found in blood samples. This study aims to determine which ctDNA tests best detect remaining cancer after surgery and chemotherapy, helping doctors decide who might need more treatment. The study is part of a larger European project called GUIDE.MRD, which includes experts and companies working together to create reliable standards for these tests. The study includes two parts in the first, blood samples are collected before and after surgery in the second, samples are taken after chemotherapy and during regular follow-up care. Patients participate in both parts separately. The study will analyze these samples to compare ctDNA tests and see if they can predict cancer recurrence earlier than current methods like imaging. Participants will be followed for three years after surgery. During this time, researchers will collect blood samples and compare ctDNA results with clinical outcomes, imaging scans, and disease-free survival. They will create a biobank of samples and assess how well ctDNA tests identify patients at high risk of cancer returning. The study involves no changes to patient treatment, which follows standard care, and aims to improve future treatment decisions.

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)